Search Medical Condition
Please enter condition
Please choose location from dropdown

Hypogonadism Clinical Trials

A listing of Hypogonadism medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (62) clinical trials

The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotrophic hypogonadism. All subjects will be treated for a maximum of 24 weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety ...

Phase

A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Phase

Attention men age 18 to 60: Are you overweight and experiencing symptoms such as low energy, reduced sex drive or mood problems? If so, you may have low testosterone levels We're currently seeking men with low testosterone for a research study of an investigational oral medication. Participation is at no ...

Phase N/A

Testosterone replacement therapy in adult, 18 years or older, males for conditions associated with a deficiency or absence of endogenous testosterone – primary hypogonadism (congenital or acquired) or secondary hypogonadism (congenital or acquired).

Phase

The primary purpose of this study is to compare the effect of testosterone replacement therapy (TRT) and matching placebo (a gel that is made to look like the TRT but does not have any testosterone drug in it) on major Cardiovascular (CV) events such as heart attack and stroke in ...

Phase

ATTENTION MEN Do you have Low Testosterone and are between the ages of 45-80? If so, you may qualify for this study of topical testosterone replacement therapy in men with low testosterone who are at increased risk for Cardiovascular disease.  

Phase

Ambulatory Blood Pressure Monitoring in Oral Testosterone Undeconate (TU, LPCN 1021) Treated Hypogonadal Men

Phase

A study for men with hypogonadal that are increased risk for cardiovascular disease with the use of topical testosterone replacement therapy.  

Phase

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22). Treatment with pembrolizumab / maraviroc combination will continue until progressive disease (PD), unacceptable adverse events (AEs), intercurrent illness that ...

Phase